m6.7pCyto-17
ICGi015-B-1
General
Cell Line |
|
hPSCreg name | ICGi015-B-1 |
Cite as: | ICGi015-B-1 |
Alternative name(s) |
m6.7pCyto-17
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease |
Last update | 12th July 2021 |
Notes | Parkinson's disease patient-specific iPSC clone with doxycycline-inducible expression of cytosolic Grx1-roGFP2 |
User feedback | |
Provider |
|
Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Derivation country | Russia |
External Databases |
|
BioSamples | SAMEA9232933 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Any
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://www.ncbi.nlm.nih.gov/sra/SRX6788805 |
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA6098112 |
Ethics
Also have a look at the ethics information for the parental line
ICGi015-B
.
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
The source cell information can be found in the parental cell line
ICGi015-B.
|
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | ||||||||||||||||||
Feeder cells |
MEF cell Cellfinder Ont Id: http://www.ebi.ac.uk/efo/EFO_0004040 |
||||||||||||||||||
Passage method |
Enzymatically
TrypLE
|
||||||||||||||||||
O2 Concentration | 20 % | ||||||||||||||||||
CO2 Concentration | 5 % | ||||||||||||||||||
Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
Alkaline Phosphatase |
Yes |
Differentiation Potency
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Genetic Modification
Disease/phenotype related modifications |
|
Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.